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Edited by Beat ImhofAbstract The NF-kB family transcription factor c-Rel is a crit-
ical molecule for inducing expression of cytokine genes by T
cells. Here, we report that a deletion of the C-terminal end, sim-
ilar to the deletion in the highly oncogenic chicken v-Rel gene,
renders c-Rel hyperactive toward cytokine gene promoters. At
the same time, this mutation dramatically reduced c-Rel activity
in induction of IkB-a mRNA expression. Moreover, ectopic
expression of IkB-a, along with the C-terminal truncated c-
Rel, abrogates hyperactivity of this mutant. IkB-a co-expression
did not aﬀect the function of wild-type c-Rel. The data demon-
strate that the C-terminal end of c-Rel has speciﬁc activity for
IkB-a mRNA expression and is dispensable for IL-2 gene
expression.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Activation of NF-kB is initiated by extracellular stimuli that
lead to activation of the IKK complex, which phosphorylates
IkB proteins [1]. In unstimulated cells, the IkB proteins com-
plex with the NF-kB subunits such as c-Rel and sequester them
from the nucleus. Phosphorylation of IkB molecules causes
proteasomal degradation of IkB proteins and release of
NF-KB molecules to the nucleus where they induce their
downstream target genes, including the IkBs. Among the IkB
molecules, IkB-a is highly inducible by NF-kB. This feedback
regulation leads to oscillation of NF-kB function when stimu-
lation is sustained over a long period of time [2].
c-Rel is an NF-kB member that is speciﬁcally expressed by
lymphoid tissues and is a critical transcription factor for
expression of cytokine genes by T cells [3–6]. It shares high
homology with other NF-kB members, RelA and RelB, within
its N-terminal half. Gene knockout mice showed that loss of c-*Corresponding author. Fax: +1 706 721 8732.
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doi:10.1016/j.febslet.2004.11.060Rel expression abrogates production of IL-2, IL-3, and GM-
CSF by naı¨ve T cells [4–7]. c-Rel binds the CD28 regulatory
element in the IL-2 promoter (CD28RE) and is required for
chromatin remodeling across the IL-2 gene promoter [8–11].
c-Rel is also known to induce the expression of IkB-a, a major
regulatory element for NF-kB family members [12].
We have recently demonstrated that nuclear accumulation of
c-Rel and cytokine induction by antigenic stimulation requires
sustained T cell receptor (TCR) engagement for over 4 h [13].
Moreover, nuclear accumulation of c-Rel requires ERK-medi-
ated signals. The regulatory process of c-Rel is clearly diﬀerent
from another NF-kB member RelA, which accumulates in the
nucleus within 30 min after stimulation [13–15].
Although the signiﬁcance of c-Rel in cytokine gene expres-
sion is well-established, the mechanistic basis of how c-Rel ex-
erts its function downstream of the TCR is not well identiﬁed.
The unique sequence of c-Rel among the NF-kB family is
found in its C-terminal half, and its function was studied
extensively with respect to oncogenesis [16–18]. To date, the
role this region plays in cytokine gene expression has not yet
been clearly characterized.
To address the questions of how c-Rel is regulated diﬀerently
from RelA and how it controls cytokine gene expression, we
performed a structure–function analysis of the c-Rel C-termi-
nal region. The results demonstrate that there are two sub-re-
gions that function independently as transcription activation
domains. The C-terminal end region is speciﬁcally required
for transcription of IkB-a gene, but is dispensable for IL-2
gene expression. Another sub-region, located closer to the N-
terminus, is required for activation of cytokine genes.2. Materials and methods
2.1. Cells, antibodies, and chemicals
Jurkat and Jurkat Tag cells, and anti-Jurkat TCR (C305) monoclo-
nal antibody (Mab) were obtained from Dr. A. Weiss (UCSF). anti-c-
Rel (sc-70), anti-p65 (RelA; sc-8008), anti-IkBa (sc-371), anti-IkBb
(sc-945), and anti-IkBe (sc7156) are from Santa Cruz Biotechnology
(San Diego, Ca), anti-human CD28 from eBioscience (San Diego,
CA), anti-Flag (M2) Mab from Sigma (St. Louis, Mo), and anti-HA
(12CA5) from Boehringer Mannheim (Mannheim, Germany). Phor-
bol-12-myristate-13-acetate (PMA) and ionomycin are from Calbio-
chem (La Jolla, CA).2.2. Plasmid constructs
Human c-Rel cDNA was purchased from American Type Culture
Collection (Rockville, MD). All of the expression plasmids contain-
ing C-terminally truncated c-Rel were constructed by PCR. The se-
quence of the 5 0 primers was: 5 0-GGA TTT TAG ATA TCT GCC
AGA TG-3 0. The 3 0 primers were: (1) 5 0-GGA CTA GTT ACT
TGA AAA AAT TCA TAT G-30 (c-Rel wild type); (2) 5 0-GCTblished by Elsevier B.V. All rights reserved.
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GCT CTA GAC ATG CTG TTA TCT GCA CAA CT-30 (D543); (4)
5 0-GCT CTA GAG CTT GCT GAC ATA CTG GAA GA-30
(D515); (5) 5 0-GGA CTA GTT CCC ATG CTG TCA CTG CTG
G-3 0 (D475); and (6) 5 0-GGA CTA GTA CTT GAG ATG GGC
CCA GGT G-30 (D376). To generate C-terminally FLAG-tagged hu-
man c-Rel and its mutants, we ligated oligonucleotides encoding a
FLAG-tag coding region [19], 5 0-GAA TTC CAG CTG AGA
TAT CTT ACG TAT TCT AGA GAC TAC AGA GAC GAC
GAT GAC AAG TAAC TAG-3 0. IkB-a cDNA was obtained from
Dr. M Boothby (Vanderbilt University, Memphis, TN). NF-AT lucif-
erase was obtained from G. Crabtree (Stanford University, Stanford,
CA). NF-kB luciferase was from J. Fujisawa (Kansai Medical Uni-
versity, Osaka, Japan). CD28RE luciferase was constructed by
replacing the NF-AT binding sequence from NF-AT luciferase with
a tandem repeat of the CD28 RE sequence [8].
2.3. Cell stimulation, immunoprecipitation and Western and Northern
blots
For Western blots, cells were stimulated with plate-coated anti-TCR
Mab (C305, 0.3 lg/ml). PMA was used at 10 ng/ml. Ionomycin was
used at 1.0 lM. For IL-2 production, the cells were stimulated with
plate-coated C305. The conditions for lysis buﬀer, immunoprecipita-
tion, and Western blots were described elsewhere [20]. Northern blots
were performed as described [21].
2.4. Transfection, luciferase assay, and IL-2 assay
For luciferase assays, cells were transfected by electroporation and
were analyzed as described [20] using the Dual-Luciferase reporter as-
say system (Promega, Madison, WI). The IL-2 assay was carried out
using kits from R&D Systems (Minneapolis, MN).3. Results and discussion
Since c-Rel shares a high homology with other NF-kB mem-
bers in the N-terminal region (referred to as the Rel homologyFig. 1. D475 enhances production and promoter activity of IL-2. (A) Schema
the FLAG epitope at the C-terminal ends. RHD: Rel homology domain, NLS
Jurkat Tag cells (a Jurkat stable transfectant line expressing SV40 large T ant
and were stimulated with serially diluted anti-TCR antibodies. The amount
amount of protein expressed was determined by anti-FLAGWestern blot and
lane 4: c-Rel. (C) Jurkat cells were transfected with deletion mutants describe
production of IL-2 was measured. (D) Jurkat Tag cells were transfected w
expression vector, or empty vector. Cells were stimulated with plate-coateddomain; RHD) [22], we created a series of deletion mutants of
the C-terminal end of c-Rel (Fig. 1A). D475 is truncated at
amino-acid residue 475, which corresponds to the truncation
found in v-Rel, an avian oncogene that produces malignant
growth of both chicken and murine primary lymphocytes
[23]. D376 has a deletion of the majority of the C-terminal half.
We compared the eﬀect of the C-terminal end truncations on
IL-2 expression (Fig. 1B). Expression of D475 dramatically en-
hanced the total level of expression of IL-2. Moreover, D475
also reduced the level of TCR stimuli required for IL-2 pro-
duction, indicating that the threshold for IL-2 production
was reduced by the expression of D475. Expression of the
wild-type c-Rel showed some enhancement over vector trans-
fectants but D376 showed little, if any, eﬀect on IL-2 produc-
tion. Thus, the region between residues 376 and 475 is
required for the expression of IL-2. Similar results were ob-
served for IL-3 production (data not shown).
To narrow the region that is responsible for the enhanced
c-Rel activity, three more C-terminal truncation mutants of
c-Rel were made. Truncation at residues 543 and 565 showed
no eﬀect on IL-2 production compared to the wild-type
c-Rel, whereas truncation at amino acid 515 caused a clear in-
crease in IL-2 production (Fig. 1C). Together, the data show
that the region between residues 475 and 543 plays a signiﬁcant
role in IL-2 expression.
To test whether the truncated forms of c-Rel enhanced IL-2
production at the transcriptional level, we next measured the
eﬀect of D475 expression on the activity of CD28RE, a known
c-Rel target in the IL-2 promoter, using the luciferase reporter
system. As shown in Fig. 1D, D475, but not the wild-type c-
Rel, enhanced the TCR-induced activity of CD28RE more
than 300% over the vector control. Thus, upregulation of IL-tic diagram of c-Rel used in this study. All constructs were tagged with
: nuclear localization signal, TD: transcriptional activation domain. (B)
igen [32]) were transfected by the expression constructs described in (A)
of IL-2 produced by each transfectant was determined by ELISA. The
is shown in the inset. Lane 1: vector control, lane 2: D396, lane 3: D475,
d in (A). Each transfectant was stimulated with anti-TCR antibody and
ith CD28 RE luciferase reporter construct together with c-Rel, D475-
anti-TCR antibody.
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promoter activity.
To further elucidate the mechanism of how truncation of the
C terminus enhanced c-Rel activity, we examined the level of
the IkB proteins expressed in c-Rel transfectants. It was re-
ported that c-Rel strongly induces the expression of IkB-a pro-
teins [12], which our data conﬁrmed (Fig. 2A). In contrast,
D475 showed little, if any, induction of the IkB-a proteins
compared to a vector-transfected control. This diﬀerence in
IkB-a induction was mediated at the level of mRNA (Fig.
2B). A Northern blot of total RNA isolated from c-Rel-trans-
fected Jurkat cells showed a signiﬁcantly higher level of IkB-a
mRNA than was present in D475 transfected cells. IkB-b
showed a small elevation of expression by c-Rel and D475.
Based on these data, we hypothesized that D475 elevates
cytokine expression because it does not induce IkB-a. This
hypothesis predicted that ectopic expression of IkB-a would
repress elevated IL-2 production by D475. To test this hypoth-
esis, we co-transfected Jurkat cells with expression constructs
for D475 and IkB-a. As shown in Fig. 2C, co-transfection of
IkB-a with D475 resulted in a clear, dose-dependent suppres-
sion of IL-2 production. In contrast to the eﬀect on D475,Fig. 2. Eﬀect of IkB-a expression on D475 function. (A) Jurkat Tag
cells were transfected with the expression construct for D475 or c-Rel.
24 h after transfection, cells were stimulated with anti-TCR antibody
for four hours. Cytoplasmic fractions from unstimulated (left panels)
and stimulated samples (right panels) were analyzed for the level of
IkB-a (upper panels) and IkB-b (lower panels). (B) Jurkat Tag cells
were transfected as in (A), and the levels of mRNA for IkB-a (upper
panel) and G3PDH (lower panel) were determined by Northern blot.
(C) Jurkat Tag cells were transfected with the expression construct for
c-Rel, D475, or vector (5 lg each) as indicated below each lane by
shaded boxes. Three diﬀerent doses of IkB-a expression construct (1, 5,
and 10 lg) were co-transfected and are indicated by numbers below. 24
h after transfection, cells were stimulated with PMA + Ionomycin for
24 h and IL-2 production was determined.IkB-a expression imposed no signiﬁcant eﬀect on the function
of the wild-type c-Rel transfectant. This suggests that the wild-
type c-Rel induces a saturating amount of enodogenous IkB-a
to control its own activity. Together, the data showed that
IkB-a overexpression speciﬁcally suppressed the enhanced
activity of D475 and indicated that the balance between IkB-
a and c-Rel protein levels is a critical determinant for the out-
come of cytokine production.
The data presented here demonstrate that the C-terminal
end (between residues 475 and 573) of c-Rel provides a nega-
tive feedback by IkB-a induction, and the region between res-
idues 376 and 475 is a positive regulator of cytokine gene
expression. Since D475 induces a marked increase of CD28RE
activity, it is unlikely that the lack of IkB-a induction by this
mutant is due to loss of transcriptional activity per se. The
presence of two distinctive transcription activation regions
was reported previously for the C-terminal half of c-Rel
[24,25]. Indeed, complete removal of the C-terminal half abro-
gated the function of c-Rel, as seen here for D396 (Fig. 1B).
Thus, we conclude that two transcriptional activation regions
in the C-terminal half of c-Rel are functionally non-redundant
and play their roles in the diﬀerent target genes; the end region
is required for the IkB-a gene and the middle region is required
for the IL-2 gene.
Control of IkB-a expression by the C-terminal end is likely
to play a biological role in the prevention of oncogenic trans-
formation. Although an eﬀect on IkB-a expression was not re-
ported, a similar deletion of D475 signiﬁcantly enhanced
transformation eﬃciency by c-Rel [25]. Given the fact that
deletion of the region corresponds to one of the major muta-
tions found in v-Rel, it is conceivable to predict that the loss
of IkB-a induction by the c-Rel C-terminal end leads to aber-
rant expression of target genes and causes oncogenic transfor-
mation.
The molecular mechanism of how this IkB-a-speciﬁc regula-
tion takes place is currently unknown. A potential mechanism
is that this region interacts with a factor that controls the pro-
moter region of IkB-a but does not aﬀect the cytokine gene
promoters. In this case, lack of the C-terminal end does not af-
fect the ability of c-Rel to enhance transcriptional activity
from cytokine genes but impairs expression of the IkB-a gene.
Although the IkB-a promoter is highly inducible by NF-kB
family members, it should be noted that glucocorticoids, which
are strong immunosuppressive agents, eﬀectively potentiated
the expression of IkB-a [26,27]. Thus, transcription factors
other than NF-kB can also contribute to upregulation of the
IkB-a gene.
Alternatively, the c-Rel C-terminal end may regulate the
mRNA level of IkB-a by a post-transcriptional mechanism.
A new member of the IkB proteins, f, was identiﬁed recently
[28–30]. IkB-f expression is induced by IL-1b and Toll-like
receptors and is controlled by post-transcriptional regulation
[31]. This raises another possibility that the C-terminal end
of c-Rel may induce or activate the machinery that stabilizes
the level of IkB-a mRNA. These possibilities are currently
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